Hyloris Pharmaceuticals (LTS:0AB6) Other Net Income (Loss) : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Hyloris Pharmaceuticals Other Net Income (Loss)?

Hyloris Pharmaceuticals's Other Net Income (Loss) for the six months ended in Dec. 2023 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

Hyloris Pharmaceuticals's quarterly Other Net Income (Loss) increased from Dec. 2022 (€-0.00 Mil) to Jun. 2023 (€0.00 Mil) but then stayed the same from Jun. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Hyloris Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for Hyloris Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Other Net Income (Loss) Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial							-	-	-	-	-

Hyloris Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Hyloris Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (LTS:0AB6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (LTS:0AB6) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

52U:Germany HYL:Belgium

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (LTS:0AB6) Headlines

No Headlines